Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H32F3N3O5 |
| Molecular Weight | 499.5232 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1)C(=O)N[C@@H](C(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(C)C)C(=O)C(F)(F)F
InChI
InChIKey=PNILZVBINXNWHW-FHWLQOOXSA-N
InChI=1S/C24H32F3N3O5/c1-13(2)18(20(31)24(25,26)27)28-22(33)17-7-6-12-30(17)23(34)19(14(3)4)29-21(32)15-8-10-16(35-5)11-9-15/h8-11,13-14,17-19H,6-7,12H2,1-5H3,(H,28,33)(H,29,32)/t17-,18-,19-/m0/s1
| Molecular Formula | C24H32F3N3O5 |
| Molecular Weight | 499.5232 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. | 2005-05-05 |
|
| Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. | 2005-05 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:16:39 GMT 2025
by
admin
on
Mon Mar 31 23:16:39 GMT 2025
|
| Record UNII |
KXL5BC5A6F
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9892148
Created by
admin on Mon Mar 31 23:16:39 GMT 2025 , Edited by admin on Mon Mar 31 23:16:39 GMT 2025
|
PRIMARY | |||
|
ZD 0892
Created by
admin on Mon Mar 31 23:16:39 GMT 2025 , Edited by admin on Mon Mar 31 23:16:39 GMT 2025
|
PRIMARY | ZD 0892 is a human neutrophil elastase inhibitor that was under development with AstraZeneca (formed by the merger of Astra and Zeneca in April 1999). | ||
|
KXL5BC5A6F
Created by
admin on Mon Mar 31 23:16:39 GMT 2025 , Edited by admin on Mon Mar 31 23:16:39 GMT 2025
|
PRIMARY | |||
|
DTXSID80938074
Created by
admin on Mon Mar 31 23:16:39 GMT 2025 , Edited by admin on Mon Mar 31 23:16:39 GMT 2025
|
PRIMARY | |||
|
171964-73-1
Created by
admin on Mon Mar 31 23:16:39 GMT 2025 , Edited by admin on Mon Mar 31 23:16:39 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |